Quantification of plasma and bone marrow VEGF and angiopoietin-2 levels in pediatric malignancies.
J Pediatr Hematol Oncol
; 34(7): 503-10, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-22735882
ABSTRACT
INTRODUCTION:
Data on angiogenesis in pediatric patients with malignancy are scarce. Our aim was to study angiogenic growth factors vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) in pediatric oncological patients at diagnosis and a few months after the beginning of the therapy. PATIENTS ANDMETHODS:
Eighty-four consecutive patients with malignancy were included in this study. The levels of plasma and bone marrow VEGF and Ang2 were analyzed by enzyme-linked immunosorbent assay.RESULTS:
The levels of VEGF were higher in patients with solid tumors than in patients with leukemias (P=0.003), whereas Ang2 concentrations showed the opposite (P=0.003). Interestingly, the plasma concentrations of both VEGF and Ang2 correlated with concentrations in the bone marrow (P<0.05). Leukemia patients with lower VEGF level and patients with higher Ang2 level at follow-up had longer event-free survival than other patients (P=0.032 and 0.053, respectively).DISCUSSION:
The results of our study enlighten the behavior of 2 different angiogenic factors in pediatric patients with malignancy. An interesting finding was the connection between survival of pediatric leukemia patients and angiogenic factor levels a few months after the beginning of therapy. Pathophysiology and clinical applications of these findings need further studies.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Medula Óssea
/
Angiopoietina-2
/
Fator A de Crescimento do Endotélio Vascular
/
Neoplasias
Limite:
Adolescent
/
Child
/
Child, preschool
/
Humans
/
Infant
/
Newborn
Idioma:
En
Revista:
J Pediatr Hematol Oncol
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Finlândia